PMID- 34335842
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231221
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Effects of Enalapril on TLR2/NF-kappaB Signaling Pathway and Inflammatory Factors in 
      Rabbits with Chronic Heart Failure.
PG  - 9594607
LID - 10.1155/2021/9594607 [doi]
LID - 9594607
AB  - Chronic heart failure (CHF) refers to the state of persistent heart failure, 
      which is a complex clinical syndrome of various advanced heart diseases. The 
      toll-like receptor 2 (TLR2)/nuclear transcription factor-kappaB (NF-kappaB) signal 
      transduction pathway is one of the pathological mechanisms of CHF. Adriamycin can 
      significantly induce the upregulation of TLR2 expression. Angiotensin-converting 
      enzyme inhibitors (ACEI) are commonly used drugs for the treatment of CHF. In our 
      study, the CHF model was established by injection of doxorubicin into the rabbit 
      ear vein. The effect of enalapril on the TLR2/NF-kappaB signaling pathway in CHF 
      rabbits has been analyzed and determined. Our research results showed that 
      enalapril reduced the inflammatory response by inhibiting the activation of the 
      TLR2/NF-kappaB signaling pathway, thereby improving cardiac structure, myocardial 
      remodeling, and cardiac function.
CI  - Copyright (c) 2021 Yanping Tang et al.
FAU - Tang, Yanping
AU  - Tang Y
AD  - Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.
FAU - Xu, Zelin
AU  - Xu Z
AD  - The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 
      410007, China.
FAU - Chen, Xinyu
AU  - Chen X
AD  - The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 
      410007, China.
FAU - Wang, Nan
AU  - Wang N
AD  - Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.
FAU - Deng, Xu
AU  - Deng X
AD  - Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.
FAU - Peng, Liqi
AU  - Peng L
AD  - Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.
FAU - Chen, Qingyang
AU  - Chen Q
AD  - The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 
      410007, China.
FAU - Cai, Huzhi
AU  - Cai H
AUID- ORCID: 0000-0001-9315-8613
AD  - The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 
      410007, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20210713
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Dec 13;2023:9828760. PMID: 38125177
PMC - PMC8294953
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2021/08/03 06:00
MHDA- 2021/08/03 06:01
PMCR- 2021/07/13
CRDT- 2021/08/02 05:57
PHST- 2021/06/17 00:00 [received]
PHST- 2021/07/01 00:00 [accepted]
PHST- 2021/08/02 05:57 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/08/03 06:01 [medline]
PHST- 2021/07/13 00:00 [pmc-release]
AID - 10.1155/2021/9594607 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Jul 13;2021:9594607. doi: 
      10.1155/2021/9594607. eCollection 2021.